p. 4849−4853
2476-762X
Vol.13/No.10
p. 4855−4860
2476-762X
Vol.13/No.10
p. 4861−4866
2476-762X
Vol.13/No.10
p. 4867−4871
2476-762X
Vol.13/No.10
p. 4873−4878
2476-762X
Vol.13/No.10
p. 4879−4881
2476-762X
Vol.13/No.10
p. 4883−4888
2476-762X
Vol.13/No.10
p. 4889−4895
2476-762X
Vol.13/No.10
p. 4897−4900
2476-762X
Vol.13/No.10
p. 4901−4903
2476-762X
Vol.13/No.10
p. 4905−4908
2476-762X
Vol.13/No.10
C) andcervical cancer risk among Asians. Methods: A literature search of Pubmed, Embase, Web of Science and CBMdatabases from inception through June 2012 was conducted. The meta-analysis was performed using STATA12.0 software. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength ofany association. Twenty-eight case-control studies were included with a total of 3,580 cervical cancer cases and3,827 healthy controls. When all the eligible studies were pooled into the meta-analysis, the results showed thatthe Pro/Pro genotype was associated with increased risk of cervical cancer under the heterozygous model (Pro/Pro vs. Arg/Pro: OR = 1.25, 95%CI: 1.02-1.53, P= 0.005). However, no statistically significant associations werefound under four other genetic models (Pro vs. Arg: OR = 0.97, 95%CI: 0.85-1.10, P= 0.624; Pro/Pro + Arg/Pro vs. Arg/Arg: OR = 0.84, 95%CI: 0.70-1.01, P= 0.058; Pro/Pro vs. Arg/Arg + Arg/Pro: OR = 1.13, 95%CI:0.92-1.39, P= 0.242; Pro/Pro vs. Arg/Arg: OR = 0.97, 95%CI: 0.76-1.22, P= 0.765; respectively). In the subgroupanalysis based on country, the Pro/Pro genotype and Pro carrier showed significant associations with increasedrisk of cervical cancer among Indian populations, but not among Chinese, Japanese and Korean populations.Conclusion: Results from the current meta-analysis suggests that p53 codon 72 polymorphism might be associatedwith increased risk of cervical cancer, especially among Indians.]]>
p. 4909−4914
2476-762X
Vol.13/No.10
p. 4915−4921
2476-762X
Vol.13/No.10
p. 4923−4926
2476-762X
Vol.13/No.10
p. 4927−4930
2476-762X
Vol.13/No.10
p. 4931−4933
2476-762X
Vol.13/No.10
p. 4935−4938
2476-762X
Vol.13/No.10
p. 4939−4941
2476-762X
Vol.13/No.10
p. 4943−4946
2476-762X
Vol.13/No.10
p. 4947−4951
2476-762X
Vol.13/No.10
p. 4953−4958
2476-762X
Vol.13/No.10
p. 4959−4962
2476-762X
Vol.13/No.10
10cm (0.0001*). The highest valueof glycated hemoglobin (8.9%) and fasting blood sugar(148.3mg/dl)in cases of renal cell carcinoma along withdiabetes mellitus was found in tumour size of 1-5cm. Conclusion: Diabetes mellitus has independent prognosticsignificance in RCC in relation to tumour size and grade]]>
p. 4963−4965
2476-762X
Vol.13/No.10
p. 4967−4971
2476-762X
Vol.13/No.10
p. 4973−4977
2476-762X
Vol.13/No.10
p. 4979−4981
2476-762X
Vol.13/No.10
C and 499C>T Polymorphisms and Skin Cancer Risk: a Meta-analysis]]>
C (rs2228001) and499C>T (rs2228000), are considered to have possible associations with the risk of skin cancer, but the reportedresults have been inconsistent. Here we performed a meta-analysis of the available evidence regarding therelationship between these two polymorphisms and the risk of skin cancer. All relevant studies were searchedusing PubMed, Embase and Web of Science before February 2012. A total of 8 case-control studies were includedin this analysis, and no convincing associations between the two polymorphisms and risk of skin cancer wereobserved in any of the genetic models. Stratified analyses by skin cancer type also did not detect significantassociations in any subgroup. This meta-analysis suggested that the XPC 939A>C and 499C>T polymorphismsmay have little involvement in susceptibility to skin cancer.]]>
p. 4983−4988
2476-762X
Vol.13/No.10
p. 4989−4992
2476-762X
Vol.13/No.10
p. 4993−4998
2476-762X
Vol.13/No.10
p. 4999−5002
2476-762X
Vol.13/No.10
p. 5003−5006
2476-762X
Vol.13/No.10
p. 5007−5010
2476-762X
Vol.13/No.10
p. 5011−5017
2476-762X
Vol.13/No.10
p. 5019−5022
2476-762X
Vol.13/No.10
p. 5023−5025
2476-762X
Vol.13/No.10
p. 5027−5031
2476-762X
Vol.13/No.10
p. 5033−5036
2476-762X
Vol.13/No.10
p. 5037−5042
2476-762X
Vol.13/No.10
p. 5043−5046
2476-762X
Vol.13/No.10
p. 5047−5052
2476-762X
Vol.13/No.10
p. 5053−5056
2476-762X
Vol.13/No.10
p. 5057−5061
2476-762X
Vol.13/No.10
p. 5063−5067
2476-762X
Vol.13/No.10
p. 5069−5074
2476-762X
Vol.13/No.10
A Polymorphism and Colorectal Cancer Risk: a Meta-analysis based on 3,019 Cases and 3,984 Controls]]>
A polymorphism is not associated with colorectal cancer risk. Because ofthe limitations of this meta-analysis, this finding demands further investigation.]]>
p. 5075−5079
2476-762X
Vol.13/No.10
p. 5081−5086
2476-762X
Vol.13/No.10
p. 5087−5090
2476-762X
Vol.13/No.10
p. 5091−5096
2476-762X
Vol.13/No.10
p. 5097−5099
2476-762X
Vol.13/No.10
T p.Q161X of the APC gene. Methods: We analyzed 20 membersof a family with AFAP. Clinical and endoscopic data were collected for phenotype determination. Genetic analysiswas also performed by direct sequencing of the APC gene. Result: Five patients with a phenotype of AFAP werefound. Endoscopic polyposis was demonstrated among the second generation with genotype mutation of thedisease (age > 50 years) consistent with delayed phenotypic adenomatous polyposis in AFAP. APC gene mutationwas identified in exon 4 of the APC gene, with mutation points of c.481C>T p.Q161X. Laparoscopic subtotalcolectomy was performed to prevent carcinogenesis. Conclusion: A family with attenuated familial adenomatouspolyposis of APC related to exon 4 mutation, c.481C>T p.Q161X, was reported and the phenotypic finding wasconfirmed by endoscopic examination. Genetic mutation analysis might be advantageous in AFAP for longterm colon cancer prevention and management due to subtle or asymptomatic phenotype presentation in earlyadulthood.]]>
p. 5101−5104
2476-762X
Vol.13/No.10
T)(rs2234693) in pre-menopausal breast cancer women showed a significant relation to increased risk (OR = 1.13,95%CI: 1.01-1.28, P = 0.040) in contrast to their post-menopausal counterparts which showed non-significantincreased risk (OR = 1.01, 95%CI: 0.87-1.18, P = 0.858). Nevertheless, no significant association between ESR1XbaI (A>G) (rs9340799) polymorphism and the risk of breast cancer was observed in pre-menopausal andpost-menopausal individuals. Conclusion: Based on a homogeneous Asian population, results from the currentmeta-analysis indicates that the ESR1 PvuII (C>T) polymorphism places pre-menopausal breast cancer womenat risk for breast cancer, while ESR1 XbaI (A>G) polymorphism is not likely to predict the risk of breast cancer.]]>
p. 5105−5111
2476-762X
Vol.13/No.10
Ser),a novel deletion of T nucleotide in an intron adjacent to intron-exon boundary and a previously determinedmissense mutation (Val>Ala). A statistically significant correlation was obtained which suggested that prohibitinmay be associated with tumor development and/or progression of at least some proportion of breast cancers.]]>
p. 5113−5117
2476-762X
Vol.13/No.10
p. 5119−5124
2476-762X
Vol.13/No.10
p. 5125−5129
2476-762X
Vol.13/No.10
p. 5131−5136
2476-762X
Vol.13/No.10
p. 5137−5142
2476-762X
Vol.13/No.10
p. 5143−5148
2476-762X
Vol.13/No.10
p. 5149−5153
2476-762X
Vol.13/No.10
p. 5155−5159
2476-762X
Vol.13/No.10
0.05). The overallsurvival and relapse-free survival rate was significantly higher in patients with negative Smad7 expression thanthose with positive Smad7 expression. Conclusion: EMT phenomena may occur in the process of CCA invasionand metastasis. Smad7, which was highly expressed in CCA, may be considered to be one feedback regulatorin late stages and could have potential as a prognostic indicator for clinical assessment.]]>
p. 5161−5165
2476-762X
Vol.13/No.10
p. 5167−5170
2476-762X
Vol.13/No.10
p. 5171−5176
2476-762X
Vol.13/No.10
p. 5177−5182
2476-762X
Vol.13/No.10
p. 5183−5188
2476-762X
Vol.13/No.10
p. 5189−5193
2476-762X
Vol.13/No.10
p. 5195−5199
2476-762X
Vol.13/No.10
p. 5201−5205
2476-762X
Vol.13/No.10
p. 5207−5211
2476-762X
Vol.13/No.10
p. 5213−5217
2476-762X
Vol.13/No.10
p. 5219−5223
2476-762X
Vol.13/No.10
p. 5225−5228
2476-762X
Vol.13/No.10
p. 5229−5232
2476-762X
Vol.13/No.10
p. 5233−5236
2476-762X
Vol.13/No.10
1 mm orwider than 2 cm and/or groin lymphnode metastases were referred for adjuvant radiotherapy. Those with largeprivary vulvar tumors received neoadjuvant radiotherapy of 30Gy followed by surgical treatment and adjuvantradiotherapy. Results: Most of patients had only primary radiotherapy to the vulva and inguinal lymph nodesand only 34.5% of patients were eligible for surgical treatment. In 5 year follow-up period 25.2% (27) patientswere alive without the disease, 15.0% (16) were alive with the disease and 59.8% (64) were dead. 60.7% (65)patients experienced local recurrence and 2.8% (3) patients had distant metastases. Median survival for patientswithout recurrent disease was 38.9±3.2 months and 36.0±2.6 months with no statistically significant difference.Patients with early stage vulvar cancer had longer mean survival rates-for stage I 53.1±3.4 months, 38.4±4.4months for stage II and 33.4±2.6 and 15.6±5.2 months for patients with stage III and stage IV vulvar cancer,respectively. The only signifficant prognostic factor predicting vulvar cancer recurrence was involvement of themidline. Conclusions: Patients having midline involvement of vulvar cancer has lower recurrence risk, probablybecause of receiving more aggressive treatment. There is a tendency for lower vulvar cancer recurrence risk forpatients over 70 years of age and patients who are receiving radiotherapy as an only treatment without surgery,but tendency for higher risk of recurrence in patients with multifocal vulvar cancer.]]>
p. 5237−5240
2476-762X
Vol.13/No.10
G variant in the exon9 of XRCC1 gene could be detected by polymerase chain reaction-restriction fragmentlength polymorphism (PCR-RFLP) and DNA sequencing methods. Significantly increased susceptibility toprostate cancer was noted in the homozygote comparison (GG versus AA: OR=2.95, 95% CI 1.46-5.42, χ2=12.36,P=0.001), heterozygote comparison (AG versus AA: OR=1.76, 95% CI 1.12-2.51, χ2=4.04, P=0.045), dominantmodel (GG/AG versus AA: OR=1.93, 95% CI 1.19-2.97, χ2=9.12, P=0.003), recessive model (GG versus AG+AA:OR=2.17, 95% CI 1.33-4.06, χ2=8.86, P=0.003) and with allele contrast (G versus A: OR=1.89, 95% CI 1.56-2.42,χ2=14.67, P<0.000). Conclusions: These findings suggest that the c.910A>G polymorphism of the XRCC1 geneis associated with susceptibility to Pca in Chinese men, the G-allele conferring higher risk.]]>
p. 5241−5243
2476-762X
Vol.13/No.10
p. 5245−5249
2476-762X
Vol.13/No.10
p. 5251−5255
2476-762X
Vol.13/No.10
p. 5257−5261
2476-762X
Vol.13/No.10
0.05). D2 lymphadenectomy-based chemotherapywas effective (HR=0.89, 95%CI: [0.80, 0.99], P=0.04). Oral S-1 40 mg/m2 after D2 lymphadenectomy mightbe a better choice for Asians with advanced GC and might result in a greater reduction of adverse events thanin non-Asian patients. GRADE quality assessment determined that the strength of the evidence from foreignstudies from Europe, the United States and Asian countries other than China was high, while it was moderatefor Chinese studies. Conclusion: AC was effective or even curative in Chinese patients in general, although it isstill necessary to optimize a targeted AC scheme for Chinese patients with GC.]]>
p. 5263−5272
2476-762X
Vol.13/No.10
p. 5273−5279
2476-762X
Vol.13/No.10
p. 5281−5286
2476-762X
Vol.13/No.10
p. 5287−5290
2476-762X
Vol.13/No.10
p. 5291−5298
2476-762X
Vol.13/No.10
p. 5299−5302
2476-762X
Vol.13/No.10
p. 5303−5306
2476-762X
Vol.13/No.10
p. 5307−5312
2476-762X
Vol.13/No.10
p. 5313−5318
2476-762X
Vol.13/No.10
p. 5319−5321
2476-762X
Vol.13/No.10
p. 5323−5324
2476-762X
Vol.13/No.10
p. 5325−5325
2476-762X
Vol.13/No.10